Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | PHASE2 | COMPLETED | 56 | — | — | Dec 1, 2004 | Jun 1, 2007 | May 23, 2011 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 40 mL of TP-38 at a 100 nanograms/mL concentration |
| Name | Type | Description |
|---|---|---|
| TP-38 | DRUG | TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38. |
Inclusion Criteria: The patients must fulfill all the following criteria: * Previous histologically-confirmed diagnosis of primary GBM (glioblastoma multiforme, glioma grade 4 at time of first diagnosis). * Histologically-confirmed and MRI diagnosed recurrent or progressive GBM after previous rese...